Advances in endocrine therapy of breast cancer proceedings of the 2003 Gleneagles Conference
Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulat...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
New York
Marcel Dekker
2004
|
| Subjects: | |
| Online Access: | Click Here to View Status and Holdings. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Add Tag MARC
| LEADER | 00000nam a2200000 i 4501 | ||
|---|---|---|---|
| 001 | wils-334449 | ||
| 005 | 202142016719 | ||
| 008 | 210520t2004 NYU af #001 deng | ||
| 020 | # | # | |a 9780824722289 |q hardback |
| 020 | # | # | |a 0824722280 |q hardback |
| 020 | # | # | |a 0932763015 |
| 040 | # | # | |a IAX |d UiTM |e rda |
| 041 | 0 | # | |a English |
| 060 | 0 | 0 | |a WP 870 |
| 090 | 0 | 0 | |a WP870 |b A2448 2004 |
| 245 | 1 | 1 | |a Advances in endocrine therapy of breast cancer |b proceedings of the 2003 Gleneagles Conference |c edited by James N. Ingle and Mitchell Dowsett |
| 264 | # | 1 | |a New York |b Marcel Dekker |c 2004 |
| 264 | # | 4 | |c ©2004 |
| 300 | # | # | |a xv, 317 pages |b illustrations (some colour) |c 24 cm |
| 336 | # | # | |a text |b txt |2 rdacontent |
| 337 | # | # | |a unmediated |b n |2 rdamedia |
| 338 | # | # | |a volume |b nc |2 rdacarrier |
| 504 | # | # | |a Includes bibliographical references and index |
| 520 | # | # | |a Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses. The authors examine clinical and translational research results from studies of these endocrine therapies and chemotherapies in pre- and postmenopausal women with early and advanced breast cancer. Advances in Endocrine Therapy of Breast Cancer provides guidance on promising new therapeutics and treatment combinations based on compelling clinical evidence |
| 650 | 1 | 2 | |a Antineoplastic Agents, Hormonal |v Congress |x therapeutic use |
| 650 | 1 | 2 | |a Breast Neoplasms |v Congresses |x drug therapy |
| 650 | 2 | 2 | |a Breast Neoplasms |v Congresses |x prevention & control |
| 650 | 2 | 2 | |a Chemotherapy, Adjuvant |v Congresses |x methods |
| 650 | # | 0 | |a Chemotherapy, Adjuvant |v Congresses |x methods |
| 700 | 1 | # | |a Ingle, James N. |c 1944- |e editor |
| 700 | 1 | # | |a Dowsett, Mitchell |e editor |
| 856 | 4 | 0 | |z Click Here to View Status and Holdings. |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=334449 |
| 964 | # | # | |c BOK |d 01 |
| 998 | # | # | |a 00264#1a006.2.2||00264#1b006.2.2||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00520##a006.2.2||00520##b006.2.2|| |
Endocrine therapies in breast cancer